C3i was on the ground at ISSCR 2026 in Montréal, where one message came through clearly: cell and gene therapy is moving from scientific promise to clinical and commercial reality. Academia and industry have taken meaningful steps forward this past year, and the momentum is building. A few takeaways stood out: Clinical progress is accelerating […]
The C3i team recently wrapped up a busy week at the BIO International Convention in San Diego, where renewed investment, artificial intelligence, and cross-border collaboration set the tone for biotech in the year ahead. Three themes stood out on the show floor: A rebounding market. Investment is picking up across the biotech ecosystem, and with […]
For the first time in Canada, blood stem cells were genetically modified using CRISPR-Cas9 technology and subsequently injected into patients as part of a North American clinical trial targeting acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Every graft used in this landmark study was produced in Montreal, at Hôpital Maisonneuve-Rosemont, through the biomanufacturing expertise […]
